AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors.
about
Leveraging Genomics for Head and Neck Cancer Treatment.AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
P2860
AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors.
@en
type
label
AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors.
@en
prefLabel
AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors.
@en
P2093
P2860
P356
P1433
P1476
AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors
@en
P2093
André Lopes Carvalho
Luciano de Souza Viana
Maicon F Zanon
Matias Melendez
Renato José Silva-Oliveira
Rui Manuel Reis
P2860
P304
53288-53301
P356
10.18632/ONCOTARGET.18395
P407
P577
2017-06-07T00:00:00Z